Qt Imaging Holdings, Inc. · NASDAQ:QTI
Qt Imaging — Investor Presentation (May 2026)
33 slides from Qt Imaging's investor presentation, May 21, 2026
Slide 1: Quantitative Transmission Imaging Breast Acoustic CT Scanner
Quantitative Transmission Imaging Breast Acoustic CT Scanner May 2026 NASDAQ:QTI Copyright ©2026 QT Imaging, Inc. All Rights Reserved.
Slide 2: Disclaimer: About This Presentation
2 Disclaimer ABOUT THIS PRESENTATION This investor presentation (this “Presentation”) is provided for informational purposes only. The information contained herein does not purport to be all-inclusive and neither QT Imaging Holdings, Inc. (the “Company”, “QT Imaging Holdings”, “QTI”), nor its respec
Slide 3: Disclaimer: Forward Looking Statements
3 Disclaimer FORWARD LOOKING STATEMENTS Certain statements included in this Presentation that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements genera
Slide 4: Our Mission: Transforming Breast Health For Every Woman
4 Our Mission Transforming Breast Health For Every Woman At QT Imaging, we are redefining what’s possible in breast imaging - delivering safe, high-resolution, and cost-effective solutions where traditional technologies fall short. Our goal is to replace outdated breast imaging workflows with the fi
Slide 5: QT Imaging Transformation
5 QT Imaging Transformation $18M from NIH to develop supplemental imaging modality to resolve dense breasts 2012-2025 Company founded by John Klock, MD 2012 FDA Clearance 2017 QTI gets delisted, public on OTC, QTIH Feb 2025 Relisted on Nasdaq Jan 2026 QTI becomes public on NASDAQ Mar 2024 Raise $18M
Slide 6: The Pain and Why QT Imaging
6 • Mammography misses cancers in dense breasts / it is painful. • MRI is expensive / slow / uncomfortable / contract injection • Ultrasound is operator dependent • Workflow is fragmented • High anxiety / recall / attrition • QT Imaging has uniquely differentiated solution • Accurate diagnosis in de
Slide 7: Primary Screening: Today's Challenge vs QT Imaging Solution
7 Primary Screening Today’s Challenge: Multi-step, patient anxiety and attrition prone process with high number of unnecessary biopsies Accurate Imaging for Dense Breasts Breast Density Confirmation Supplemental Screening QT Imaging Solution: Single step (Supplemental + Dx) patient friendly process,
Slide 8: QT Imaging Value Proposition
8 QT Imaging Value Proposition • One-stop-shop supplemental + diagnostic imaging • No radiation, no compression, no contrast • Low recall, less anxiety • Operator independent • One test – multiple results (MRI like Imaging) • Calcium visualization (DCIS + Ca, Density, Doubling, Cyst/Solid, Implant)
Slide 9: Our Technology and Product
9 Reflection transducers Transmission mode receiver Transmission mode transmitter Our Technology and Product • FDA-cleared, patent protected breast imaging modality • Pain free, safe, no radiation or contrast • Inherently 3D quantitative, imaging modality, thus it’s high resolution, similar to MRI •
Slide 10: Optimized Patient Experience
10 Optimized Patient Experience • No ionizing radiation. Acoustic source only • No breast compression and associated discomfort • 10-12 minutes per breast exam time • Quiet and comfortable (compared to MRI – claustrophobia, coil pressure, noise, lengthy exams) • No contrast injection or associated r
Slide 11: Quantitative Imaging Platform Enables AI and Biomarker Expansion
11 Quantitative Imaging Platform Enables AI and Biomarker Expansion • Unique quantitative data: Speed of Sound, Attenuation, Reflection, Nakagami parameters etc. • Early detection of malignancy using defined quantitative thresholds • Therapy monitoring such as pathological complete response (pCR) pr
Slide 12: Our Market, Why Now, and How It Fits In
Our Market, Why Now, and How It Fits In
Slide 13: QT Imaging's Technology Has the Opportunity to Transform the Breast Imaging Market
13 (1) https://www.futuremarketinsights.com/reports/automated-breast-ultrasound-system-market (2) https://www.grandviewresearch.com/industry-analysis/breast-imaging-equipment-market $5.45B for 2024 with 8.9% CAGR. (3) https://www.archivemarketresearch.com/reports/breast-cancer-biomarkers-316622 (4)
Slide 14: Many Women Have Dense Breasts, Which Mammograms Screen Inefficiently
14 Many Women Have Dense Breasts, Which Mammograms are Inefficient in Screening for Cancer The FDA Has Recognized the Importance of Breast Density in Breast Cancer Screening FDA Density Disclosure Requirements 50% of women between the ages of 40-74 in the U.S. have dense breasts(1) 50%50% Mammograph
Slide 15: AI Adoption in Radiology and Personalized Oncology/Biomarkers
15 AI Adoption in Radiology and Personalized Oncology/Biomarkers QT Imaging is uniquely positioned at the intersection of two major healthcare shifts: AI-enabled radiology workflows and quantitative biomarker driven precision oncology. Radiology is the leading specialty for clinical AI adoption • ~3
Slide 16: Category III CPT Code Approval – X579T
16 Category III CPT Code Approval – X579T • Submitted on November 3, 2025 • Approved by AMA in February 2026 • Scheduled for release on July 1, 2026, with an effective date of January 1, 2027 ➢The new Category III code, X579T, represents a significant milestone in the clinical and commercial advance
Slide 17: Breast Cancer Screening Matrix: QT Imaging Sweet Spot
17 Breast Cancer Screening Matrix: QT Imaging Sweet Spot Risk Category (Tyrer-Cuzick Lifetime Risk) + Breast Density Typical Risk Profile Description < 40 Years ≥ 40 Years Low Risk (<12%) (~20–30% of women) No first-degree relatives with breast cancer No known pathogenic mutations No prior chest rad
Slide 18: Validation
gg QT IMAGING Validation ~ a Se
Slide 19: Validation
19 Validation • Existing FDA clearance to offer an imaging modality for all patients above 18 years old • Received UAE regulatory approval • NIH $18M funding to generate a safe imaging modality for women with dense breasts • Ongoing clinical studies at: −Mayo Clinic −Sunnybrook Cancer Center −To sta
Slide 20: Clinical Validation: Mayo Clinic – QTscan vs MRI
20 Clinical Validation Across Screening and Oncology Applications: Mayo Clinic – QTscan vs MRI • Mayo Clinic prospective feasibility study: 26 high-risk women comparing QT Imaging (QTscan) with breast MRI for supplemental screening • Strong breast-level agreement with MRI: binary agreement between Q
Slide 21: Clinical Validation: Sunnybrook Cancer Center – QTscan vs MRI
21 MRI Clinical Validation Across Screening & Oncology Applications: Sunnybrook Cancer Center – QTscan vs MRI • NIH/NCI-funded, to prove QT Imaging as imaging modality for early monitoring of breast cancer response to neoadjuvant chemotherapy (NAC) • Major oncology need: − treatment response that ca
Slide 22: Regulatory Activities Additional to FDA Clearance
22 Regulatory Activities Additional to FDA Clearance Saudi FDA (SFDA) UAE MOHAP Submit Dossier —Feb, 2026 Authorized Rep via Gulf Medical; MDS-GS-004 Under SFDA Regulatory Review Expected Marketing Authorization Target: Q2 2026 Dossier Preparation Leverage SFDA submission; MOHAP registration UAE Sub
Slide 23: Business Model, Partnerships & Financial Trajectory
Business Model, Partnerships & Financial Trajectory
Slide 24: Business Model: HW + SaaS + AI Diagnostic Layer
24 Business Model HW+ SaaS +AI Diagnostic Layer Business Model: • Hardware sale (scanner): upfront revenue • SaaS platform: recurring revenue • AI diagnostic layer: higher margin Radiology Cloud SaaS Platform Referring MD Hardware gets us in the door. Software builds the company. Copyright ©2026 QT
Slide 25: Business Partnerships Today
25 Business Partnerships Today Under Distribution Agreement with NXC Imaging (Subsidiary of Canon Medical Systems) for U.S. market Under Contract Manufacturing Agreement with Canon Medical Systems Under Distribution Agreement with Gulf Medical for Kingdom of Saudi Arabia (KSA) market Under Distribut
Slide 26: Business Partnerships: U.S. and International Expansion
26 • Under Distribution Agreement with NXC Imaging (Subsidiary of Canon Medical Systems) for U.S.A. market − Four additional distributors signed by NXC Imaging to cover sales across all states − Committed quarterly minimum order quantities (MOQs) for scanner shipments till end of 2026 Business Partn
Slide 27: QTI Precision Pathway – Cloud SaaS Platform
27 QTI Precision Pathway – Cloud SaaS Platform Core Operational Advanced Enterprise System software updates Long term technology relevance Collaboration & data sharing Quantitated biomarkers Automated analysis Precision reporting Multiuser access Enterprise collaboration Scanner Evergreen QTI Precis
Slide 28: Financial Trajectory: Revenue and Scanner Shipments
28 Financial Trajectory 4 4 2 2 6 8 9 17 13 0 2 4 6 8 10 12 14 16 18 $- $1.00 $2.00 $3.00 $4.00 $5.00 $6.00 $7.00 $8.00 $9.00 Q1 2024 A Q2 2024 A Q3 2024 A Q4 2024 A Q1 2025 A Q2 2025 A Q3 2025 A Q4 2025 A Q1 2026 F S h ip m e n ts ( # ) R e ve n u e ( $ M ) Quarterly Revenue and Scanner Shipments R
Slide 29: Financial Trajectory: Unit Economics per Scanner
29 Financial Trajectory QT Imaging is scaling a commercial business. $407 $473 $488 $(613) $(88) $8 54% 45% 45% -100% -80% -60% -40% -20% 0% 20% 40% 60% 80% 100% $(700) $(600) $(500) $(400) $(300) $(200) $(100) $- $100 $200 $300 $400 $500 $600 FY 2024 A FY 2025 A FY 2026 F Revenue/scanner, Gross Mar
Slide 30: Competitive Sales Cycle and Clinical Sites Adoption Curve
30 Competitive Sales Cycle and Clinical Sites Adoption Curve QT Imaging’s differentiated value proposition enables adoption timelines competitive with incumbent imaging technologies. Segment/ Sales Cycle Existing Imaging Equipment QT Imaging Equipment Hospital 12 to 18 months 6 to 8 months Outpatien
Slide 31: Planned Evolution to Hybrid Commercial Model as Scale Increases
31 Planned Evolution to Hybrid Commercial Model as Scale Increases Commercial strategy balances capital efficiency today with increasing control and margin expansion over time. 2026 2027-2028 Long term Distributor Led Hybrid Model Selective Direct Sales • Broad market coverage • Capital efficient •
Slide 32: QT Imaging Is Executing on Its Early Commercial Scale
32 QT Imaging Is Executing on Its Early Commercial Scale With Multiple Near Term Value Inflection Points • FDA cleared, clinically validated technology addressing a large unmet need in dense breast imaging – this is a category-defining company at the exact moment the market is ready • Commercial inf
Slide 33: Thank You!
gg QT IMAGING Thank You! | —
QT Imaging Holdings — Investor Presentation (May 2026) on 6ix